Bioloģiskās terapijas efektivitāte pacientiem ar poliartikulāru un sistēmas juvenilu idiopātisku artrītu

Introduction. Biological drug is indicated for the treatment of JIA if previous treatment with
traditional drug has not been effective or intolerance to traditional drug is proven. For the treatment
of JIA, the indicated groups of the biological drugs are: IL-6-receptor blocker Tocilizumab (TCZ); TNF-α
inhibitors Etanercept (ETN), Adalimumab (ADA) and T-cell co-stimulation modulator of Abatacept (ABA).
Therapeutic efficacy is observed using ACR Pedi criteria of improvement.
Aim. The aim of the research is to evaluate the effectiveness of biological therapy for patients
with polyarticular juvenile idiopathic arthritis (pJIA) and systemic juvenile idiopathic arthritis (sJIA) in
3 months, for which therapy with MTX is ineffective or MTX intolerance is proven.
Material and methods. In the research, the data of 70 patients from Children’s Clinical University
Hospital and the outpatient treatment department are analyzed, for which decisions were taken by
the Councils on the initiation of biological therapy during the period from January, 2010 to October, 2012.
The efficacy of biological therapy was evaluated in 3 months.Introduction. Biological drug is indicated for the treatment of JIA if previous treatment with
traditional drug has not been effective or intolerance to traditional drug is proven. For the treatment
of JIA, the indicated groups of the biological drugs are: IL-6-receptor blocker Tocilizumab (TCZ); TNF-α
inhibitors Etanercept (ETN), Adalimumab (ADA) and T-cell co-stimulation modulator of Abatacept (ABA).
Therapeutic efficacy is observed using ACR Pedi criteria of improvement.
Aim. The aim of the research is to evaluate the effectiveness of biological therapy for patients
with polyarticular juvenile idiopathic arthritis (pJIA) and systemic juvenile idiopathic arthritis (sJIA) in
3 months, for which therapy with MTX is ineffective or MTX intolerance is proven.
Material and methods. In the research, the data of 70 patients from Children’s Clinical University
Hospital and the outpatient treatment department are analyzed, for which decisions were taken by
the Councils on the initiation of biological therapy during the period from January, 2010 to October, 2012.
The efficacy of biological therapy was evaluated in 3 months.Introduction. Biological drug is indicated for the treatment of JIA if previous treatment with
traditional drug has not been effective or intolerance to traditional drug is proven. For the treatment
of JIA, the indicated groups of the biological drugs are: IL-6-receptor blocker Tocilizumab (TCZ); TNF-α
inhibitors Etanercept (ETN), Adalimumab (ADA) and T-cell co-stimulation modulator of Abatacept (ABA).
Therapeutic efficacy is observed using ACR Pedi criteria of improvement.
Aim. The aim of the research is to evaluate the effectiveness of biological therapy for patients
with polyarticular juvenile idiopathic arthritis (pJIA) and systemic juvenile idiopathic arthritis (sJIA) in
3 months, for which therapy with MTX is ineffective or MTX intolerance is proven.
Material and methods. In the research, the data of 70 patients from Children’s Clinical University
Hospital and the outpatient treatment department are analyzed, for which decisions were taken by
the Councils on the initiation of biological therapy during the period from January, 2010 to October, 2012.
The efficacy of biological therapy was evaluated in 3 months.Introduction. Biological drug is indicated for the treatment of JIA if previous treatment with
traditional drug has not been effective or intolerance to traditional drug is proven. For the treatment
of JIA, the indicated groups of the biological drugs are: IL-6-receptor blocker Tocilizumab (TCZ); TNF-α
inhibitors Etanercept (ETN), Adalimumab (ADA) and T-cell co-stimulation modulator of Abatacept (ABA).
Therapeutic efficacy is observed using ACR Pedi criteria of improvement.
Aim. The aim of the research is to evaluate the effectiveness of biological therapy for patients
with polyarticular juvenile idiopathic arthritis (pJIA) and systemic juvenile idiopathic arthritis (sJIA) in
3 months, for which therapy with MTX is ineffective or MTX intolerance is proven.
Material and methods. In the research, the data of 70 patients from Children’s Clinical University
Hospital and the outpatient treatment department are analyzed, for which decisions were taken by
the Councils on the initiation of biological therapy during the period from January, 2010 to October, 2012.
The efficacy of biological therapy was evaluated in 3 months.Results. JIA patients were between the ages of 2 to 18. ETN was received by 46 (71%) of the pJIA
patients, average disease duration, starting treatment with ETN was 2.85 years, and ACR Pedi 30 was
reached by 34 (74%) patients, ACR Pedi 50 – 22 (48%), ACR Pedi 70 – 1 (2%). ABA was received by 12 (18%)
of the pJIA patients, the average duration of the disease, starting treatment with ABA – 3.92 years and
ACR Pedi 30 was reached by 9 (75%) patients, ACR Pedi 50 – 7 (58%), ACR Pedi 70 – 1 (8%). ADA was
received by 7 (11%) of the pJIA patients, the average duration of the disease, starting treatment with
ADA – 3.17 years and ACR 30 Pedi was reached by 5 (71%) patients, ACR Pedi 50 – 4 (57%), ACR Pedi
70 – 1 (14%). TCZ was received by 5 (100%) of the sJIA patients, the average disease duration, starting
treatment with TCZ – 3.4 years and ACR Pedi 30 was reached by 4 (80%) patients, ACR Pedi 50 – 4 (80%),
ACR Pedi 70 – 1 (20%).
Conclusions. In 3 months, biological therapy is effective for 74% pJIA in the ETN group, 71% pJIA
in the ADA group, 75% pJIA in the ABA group and 80% sJIA in the TCZ group, achieving mainly 30–50%
improvement in 3 months using ACR Pedi criteria.